BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32123578)

  • 1. Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy.
    Aubry A; Yu T; Bremner R
    Cell Death Discov; 2020; 6():2. PubMed ID: 32123578
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
    Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L
    Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus.
    Flores-Martínez YA; Le-Trilling VTK; Trilling M
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
    Luo Z; Pan Y; Jeong LS; Liu J; Jia L
    Autophagy; 2012 Nov; 8(11):1677-9. PubMed ID: 22874562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.
    Jia L; Li H; Sun Y
    Neoplasia; 2011 Jun; 13(6):561-9. PubMed ID: 21677879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer.
    Pan WW; Zhou JJ; Yu C; Xu Y; Guo LJ; Zhang HY; Zhou D; Song FZ; Fan HY
    J Biol Chem; 2013 Oct; 288(41):29680-91. PubMed ID: 23995842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.
    Lan H; Tang Z; Jin H; Sun Y
    Sci Rep; 2016 Apr; 6():24218. PubMed ID: 27063292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SCF
    Roberts JZ; Holohan C; Sessler T; Fox J; Crawford N; Riley JS; Khawaja H; Majkut J; Evergren E; Humphreys LM; Ferris J; Higgins C; Espona-Fiedler M; Moynagh P; McDade SS; Longley DB
    Cell Death Differ; 2020 Sep; 27(9):2726-2741. PubMed ID: 32313199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Inhibition of the E3 Ligase SCF
    Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
    Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma.
    Salaroglio IC; Belisario DC; Bironzo P; Ananthanarayanan P; Ricci L; Digiovanni S; Fontana S; Napoli F; Sandri A; Facolmatà C; Libener R; Comunanza V; Grosso F; Gazzano E; Leo F; Taulli R; Bussolino F; Righi L; Papotti MG; Novello S; Scagliotti GV; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2022 Feb; 41(1):75. PubMed ID: 35197103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.
    Luo Z; Yu G; Lee HW; Li L; Wang L; Yang D; Pan Y; Ding C; Qian J; Wu L; Chu Y; Yi J; Wang X; Sun Y; Jeong LS; Liu J; Jia L
    Cancer Res; 2012 Jul; 72(13):3360-71. PubMed ID: 22562464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
    Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
    EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
    Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
    Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of neddylation and deneddylation of cullin1 in SCFSkp2 ubiquitin ligase by F-box protein and substrate.
    Bornstein G; Ganoth D; Hershko A
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11515-20. PubMed ID: 16861300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
    Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation.
    Li X; Pham V; Tippin M; Fu D; Rendon R; Song L; Uchio E; Hoang BH; Zi X
    Cell Commun Signal; 2019 Mar; 17(1):25. PubMed ID: 30885218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.
    Wang X; Zhang W; Yan Z; Liang Y; Li L; Yu X; Feng Y; Fu S; Zhang Y; Zhao H; Yu J; Jeong LS; Guo X; Jia L
    Oncotarget; 2016 Jun; 7(25):38380-38391. PubMed ID: 27224919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of tumor angiogenesis by targeting the protein neddylation pathway.
    Yao WT; Wu JF; Yu GY; Wang R; Wang K; Li LH; Chen P; Jiang YN; Cheng H; Lee HW; Yu J; Qi H; Yu XJ; Wang P; Chu YW; Yang M; Hua ZC; Ying HQ; Hoffman RM; Jeong LS; Jia LJ
    Cell Death Dis; 2014 Feb; 5(2):e1059. PubMed ID: 24525735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.
    Yang D; Tan M; Wang G; Sun Y
    PLoS One; 2012; 7(3):e34079. PubMed ID: 22457814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy.
    Zhou LN; Xiong C; Cheng YJ; Song SS; Bao XB; Huan XJ; Wang TY; Zhang A; Miao ZH; He JX
    Neoplasia; 2022 Oct; 32():100823. PubMed ID: 35907292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.